UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000060228
Receipt number R000068887
Scientific Title The National Registry of Corneal Endothelial Damage after Glaucoma Surgery in Japan
Date of disclosure of the study information 2026/02/01
Last modified on 2025/12/29 08:47:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The National Registry of Corneal Endothelial Damage after Glaucoma Surgery in Japan

Acronym

NR-CEGlaS

Scientific Title

The National Registry of Corneal Endothelial Damage after Glaucoma Surgery in Japan

Scientific Title:Acronym

NR-CEGlaS

Region

Japan


Condition

Condition

Glaucoma

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In recent years, the range of glaucoma surgical procedures has expanded, enabling stage-specific treatment selection. However, in some cases, irreversible complications such as corneal endothelial cell damage can occur after glaucoma surgery, which remains a major challenge in glaucoma management. This study aims to generate foundational data to support the development of future guidance on indications, postoperative care, and prevention of endothelial damage in glaucoma surgery by investigating the real-world burden and incidence of postoperative corneal endothelial cell damage and by establishing effective treatment strategies.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Percentage change in central corneal endothelial cell density at 12 months postoperatively

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who underwent glaucoma surgery combined with cataract extraction at the participating institutions during the study period, including drainage device implantation, trabeculotomy, trabeculectomy, PreserFlo MicroShunt implantation, Ex-PRESS shunt implantation, and other glaucoma device implantation procedures.

Key exclusion criteria

Patients lacking preoperative corneal endothelial cell evaluation, as well as those judged unsuitable for inclusion by the principal investigator or sub-investigators at each participating center.

Target sample size

3000


Research contact person

Name of lead principal investigator

1st name Tsutomu
Middle name
Last name Inatomi

Organization

National Center for Geriatrics and Gerontology

Division name

Department of Ophthalmology

Zip code

474-8511

Address

7-430 Morioka-cho, Obu City, Aichi Prefecture, Japan

TEL

0562-46-2311

Email

tinatomi@koto.kpu-m.ac.jp


Public contact

Name of contact person

1st name Yo
Middle name
Last name Okada

Organization

National Center for Geriatrics and Gerontology

Division name

Department of Ophthalmology

Zip code

474-8511

Address

7-430 Morioka-cho, Obu City, Aichi Prefecture, Japan

TEL

0562-46-2311

Homepage URL


Email

y-okada@koto.kpu-m.ac.jp


Sponsor or person

Institute

National Center for Geriatrics and Gerontology

Institute

Department

Personal name



Funding Source

Organization

Japan Glaucoma Society

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Ethics and Conflict of Interest Committee, National Center for Geriatrics and Gerontology

Address

7-430 Morioka-cho, Obu City, Aichi Prefecture, Japan

Tel

0562-46-2311

Email

yaday@ncgg.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 02 Month 01 Day

Date of IRB


Anticipated trial start date

2026 Year 02 Month 01 Day

Last follow-up date

2030 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a multicenter retrospective observational study with no interventional procedures.
Patients who underwent glaucoma surgery combined with cataract extraction at participating institutions between October 1, 2021, and September 30, 2024 are eligible. The glaucoma procedures include drainage device implantation, trabeculotomy, trabeculectomy, PreserFlo MicroShunt implantation, Ex-PRESS shunt implantation, and other glaucoma device implantation surgeries.
The primary factor (exposure) of interest is the surgical procedure category as defined above. The primary outcome is the percentage change in central corneal endothelial cell density at 12 months postoperatively. Sampling will include consecutive (or all eligible) cases at each site, and data will be collected from existing clinical records.


Management information

Registered date

2025 Year 12 Month 29 Day

Last modified on

2025 Year 12 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068887